{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T21:19:04Z","timestamp":1792876744150,"version":"4.5.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Chem Res"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00044-026-03612-8","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T04:36:53Z","timestamp":1787632613000},"page":"1548-1552","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Centanafadine (Simtriyo\u00ae): a first-in-class triple reuptake inhibitor approved for attention-deficit\/hyperactivity disorder (ADHD)"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1799-5652","authenticated-orcid":false,"given":"Longqin","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"issue":"6","key":"3612_CR1","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/syn.21538","volume":"66","author":"FP Bymaster","year":"2012","unstructured":"Bymaster FP, Golembiowska K, Kowalska M, Choi YK, Tarazi FI. Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: Implications for treatment of attention-deficit hyperactivity disorder. Synapse. 2012;66(6):522\u201332. https:\/\/doi.org\/10.1002\/syn.21538.","journal-title":"Synapse"},{"key":"3612_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.neubiorev.2018.02.001","volume":"87","author":"SV Faraone","year":"2018","unstructured":"Faraone SV. The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit\/hyperactivity disorder and other psychiatric comorbidities. Neurosci Biobehavioral Reviews. 2018;87:255\u201370. https:\/\/doi.org\/10.1016\/j.neubiorev.2018.02.001.","journal-title":"Neurosci Biobehavioral Reviews"},{"issue":"3","key":"3612_CR3","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1124\/jpet.106.116483","volume":"321","author":"AS Basile","year":"2007","unstructured":"Basile AS, Janowsky A, Golembiowska K, Kowalska M, Tam E, Benveniste M, et al. Characterization of the Antinociceptive Actions of Bicifadine in Models of Acute, Persistent, and Chronic Pain. J Pharmacol Exp Ther. 2007;321(3):1208\u201325. https:\/\/doi.org\/10.1124\/jpet.106.116483.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"3612_CR4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0014-2999(03)01310-4","volume":"461","author":"P Skolnick","year":"2003","unstructured":"Skolnick P, Popik P, Janowsky A, Beer B, Lippa AS. Antidepressant-like actions of DOV 21,947: a triple reuptake inhibitor. Eur J Pharmacol. 2003;461(2):99\u2013104. https:\/\/doi.org\/10.1016\/S0014-2999(03)01310-4.","journal-title":"Eur J Pharmacol"},{"key":"3612_CR5","unstructured":"Skolnick P, Chen Z, Basile A, Epstein JW. inventors; Dov Pharmaceutical, Inc., assignee. 1-Aryl-3-azabicyclo[3.1.0]hexanes, processes for preparing them, pharmaceutical compositions containing them, and their uses in the treatment of neuropsychiatric disorders patent WO2007016155. 2007."},{"key":"3612_CR6","unstructured":"US Food & Drug Administration. NDA approval Letter. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2026\/218145Orig1s000ltr.pdf. Published 7\/24\/2026. Accessed 8\/7\/2026."},{"key":"3612_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41467-025-66670-3","volume":"17","author":"Y Li","year":"2026","unstructured":"Li Y, Meng Y, Li N, Zhao J, Li R, Bai Q, et al. Structural basis for pharmacotherapeutic action of triple reuptake inhibitors. Nat Commun. 2026;17:61. https:\/\/doi.org\/10.1038\/s41467-025-66670-3.","journal-title":"Nat Commun"},{"key":"3612_CR8","doi-asserted-by":"publisher","first-page":"780921","DOI":"10.3389\/fpsyt.2021.780921","volume":"12","author":"D Fu","year":"2021","unstructured":"Fu D, Wu DD, Guo HL, Hu YH, Xia Y, Ji X, et al. The Mechanism, Clinical Efficacy, Safety, and Dosage Regimen of Atomoxetine for ADHD Therapy in Children: A Narrative Review. Front Psychiatry. 2021;12:780921. https:\/\/doi.org\/10.3389\/fpsyt.2021.780921.","journal-title":"Front Psychiatry"},{"issue":"6","key":"3612_CR9","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.jaac.2025.06.023","volume":"65","author":"CL Ward","year":"2026","unstructured":"Ward CL, Childress AC, Jin N, Turkoglu O, Skubiak T, Wilens TE. Centanafadine for Attention-Deficit\/Hyperactivity Disorder in Adolescents: A Randomized Clinical Trial. J Am Acad Child Adolesc Psychiatry. 2026;65(6):805\u201317. https:\/\/doi.org\/10.1016\/j.jaac.2025.06.023.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"3612_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.tips.2014.11.006","volume":"36","author":"HH Sitte","year":"2015","unstructured":"Sitte HH, Freissmuth M. Amphetamines, new psychoactive drugs and the monoamine transporter cycle. Trends Pharmacol Sci. 2015;36(1):41\u201350. https:\/\/doi.org\/10.1016\/j.tips.2014.11.006.","journal-title":"Trends Pharmacol Sci"},{"key":"3612_CR11","unstructured":"U.S. Food and Drug Administration. Highlights of prescribing information: Simtriyo\u00ae (centanafadine) extended-release capsules, for oral use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/218145s000lbl.pdf. Published 07\/2026. Accessed 8\/7\/2026."},{"issue":"3","key":"3612_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1542\/pedsos.2024-000349","volume":"1","author":"CL Ward","year":"2025","unstructured":"Ward CL, Wilens TE, Jin N, Turkoglu O, Skubiak T, Childress AC. Efficacy and Safety of Centanafadine for ADHD Treatment in Children: A Randomized Clinical Trial. Pediatr Open Sci. 2025;1(3):1\u201311. https:\/\/doi.org\/10.1542\/pedsos.2024-000349.","journal-title":"Pediatr Open Sci"}],"container-title":["Medicinal Chemistry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-026-03612-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00044-026-03612-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-026-03612-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:04:12Z","timestamp":1788343452000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00044-026-03612-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":12,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3612"],"URL":"https:\/\/doi.org\/10.1007\/s00044-026-03612-8","relation":{},"ISSN":["1054-2523","1554-8120"],"issn-type":[{"value":"1054-2523","type":"print"},{"value":"1554-8120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"assertion":[{"value":"8 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declares no competing interests.","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}